公司資料
MannKind 股價、新聞與催化劑
- 股票代碼:
- MNKD
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
3.90 USD (+1.30%)
收盤價
最後更新: 2026年8月17日
1.06B USD
市值
股價為何變動
As of Aug 17, 2026, MNKD closed up 1.30% at $3.90. No new same-company headline was identified in the current news window.
公司概覽
Inhaled Drug Delivery
MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery.
Commercial Portfolio
Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid overload outside traditional infusion settings.
MNKD-201
MNKD-201 is an inhaled dry-powder formulation of nintedanib being advanced for idiopathic pulmonary fibrosis through the INFLO clinical program.
Ralinepag DPI
MNKD-1501 is an inhaled ralinepag program being developed with United Therapeutics for pulmonary hypertension.
Orphan-Lung Pipeline
MannKind is applying its pulmonary-delivery expertise to additional orphan lung diseases, including conditions that currently require prolonged multidrug treatment.
未來催化劑
- First patient enrollment in the Phase 2 INFLO-2 study of MNKD-201 in the second quarter of 2026.
- FDA action on the pediatric Afrezza indication by May 29, 2026.
- FDA action on the FUROSCIX ReadyFlow autoinjector by July 26, 2026.
- Topline Phase 1b INFLO-1 data for MNKD-201 in the third quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。